加载中
NASDAQHealthcareMedical - Devices
最新数据
US$4.08
+US$0.02 · +0.49%
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
常规交易时段
US$4.08
+US$0.02 · +0.49%
盘中时间采用ET。市场数据可能有所延迟。
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
日内区间
当前US$4.08
52周区间
当前US$4.08
盘中时间采用ET。市场数据可能有所延迟。
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
日内区间
当前US$4.08
52周区间
当前US$4.08
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4515.1万 USD | 2943.1万 USD | 1851.1万 USD | 1239.8万 USD | 840.1万 USD |
| 销货成本 | 696.5万 USD | 410.3万 USD | 260.5万 USD | 225.8万 USD | 119.3万 USD |
| 毛利 | 3818.6万 USD | 2532.8万 USD | 1590.6万 USD | 1014万 USD | 720.8万 USD |
| 研究与开发 | 1496.5万 USD | 1768.8万 USD | 2983.5万 USD | 2135.8万 USD | 1422.4万 USD |
| 销售、一般及管理费用 | 5016.7万 USD | 4380.5万 USD | 4054.6万 USD | 2522.1万 USD | 1701.6万 USD |
| 营业费用 | 6513.2万 USD | 6149.3万 USD | 7038.1万 USD | 4657.9万 USD | 3124万 USD |
| 利息收入 | 55.5万 USD | 40.4万 USD | 43.1万 USD | 18万 USD | — |
| 利息支出 | 554.4万 USD | 309万 USD | 1.6万 USD | 1000 USD | 176.1万 USD |
| 折旧和摊销 | 62.6万 USD | 74.4万 USD | 68.4万 USD | 39.8万 USD | 46.4万 USD |
| 营业利润 | −2694.6万 USD | −3616.5万 USD | −5447.5万 USD | −3643.9万 USD | −2403.2万 USD |
| 净利润 | −3922.7万 USD | −3323.3万 USD | −5936.3万 USD | −4718.7万 USD | −2884.5万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$11.00
上涨空间 169.61%评级样本有限，仅4项
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI565.23万0.00%2.3万亿 USD0.03%US$381.47-0.12%
iShares Russell 2000 ETFIWM459.64万0.01%787.4亿 USD0.19%US$278.23-0.25%
Vanguard Extended Market ETFVXF270.15万0.00%954亿 USD0.05%US$233.91-0.47%
iShares Russell 2000 Growth ETFIWO168.23万0.01%139.17亿 USD0.24%US$354.12-0.75%
Vanguard Russell 2000 ETFVTWO135.94万0.01%180亿 USD0.06%US$112.39-0.24%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS121.94万0.31%3.99亿 USD0.60%US$106.28-0.90%
iShares Micro-Cap ETFIWC56.38万0.04%13.17亿 USD0.60%US$181.98-0.56%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM26万0.22%1.17亿 USD0.73%US$15.86-0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOInvesco Dorsey Wright SmallCap Momentum ETFDWASiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
